Effects of cardioactive drugs on human induced pluripotent stem cell derived long QT syndrome cardiomyocytes

SpringerPlus

Table 1 Details of the control and patient-specific pluripotent stem cell lines used for drug testing

Cell line	Line type	Mutation	Disease	Affected current	Source	Purpose
H7 (hESC)	hESC	Wild type	None	None	ICM	hESC control
UTA.00112.hFF (WTa)	hiPSC	Wild type	None	None	hFF	Control
UTA.01006.WT (WTb)	hiPSC	Wild type	None	None	hADF	Adult control
UTA.00208.LQT1^θ,*^,s	hiPSC	G589D	LQT1	I_Ks	hADF	Symptomatic, patient-specific
UTA.00211.LQT1^θ,*^,s	hiPSC	G589D	LQT1	I_Ks	hADF	Symptomatic, patient-specific
UTA.00303.LQT1^ψ,*^,a	hiPSC	G589D	LQT1	I_Ks	hADF	Asymptomatic mutation carrier-specific
UTA.00313.LQT1^ψ,*^,a	hiPSC	G589D	LQT1	I_Ks	hADF	Asymptomatic mutation carrier-specific
UTA.00514.LQT2^‡,a	hiPSC	R176W	LQT2	I_Kr	hADF	Asymptomatic mutation carrier-specific
UTA.00525.LQT2^‡,a	hiPSC	R176W	LQT2	I_Kr	hADF	Asymptomatic mutation carrier-specific

ICM inner cell mass of blastocyst, hFF human foreskin fibroblast, hADF human adult dermal fibroblast, hESC human embryonic stem cell, hiPSC human induced pluripotent stem cell
* Siblings ^{‡, θ, ψ} clonal lines from same individual ^s symptomatic ^a asymptomatic